Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
22 February 2023 - 11:22PM
Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global
biopharmaceutical company and leader in complement, today announced
that it has commenced an underwritten public offering of $300
million of its common stock (or pre-funded warrants to purchase its
common stock in lieu thereof). All of the shares of common stock
and pre-funded warrants are being offered by Apellis. In addition,
Apellis expects to grant the underwriters a 30-day option to
purchase additional shares of its common stock in an amount equal
to 15% of the securities offered in the public offering.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and
Evercore Group L.L.C. are acting as joint book-running managers for
the offering. Robert W. Baird & Co. Incorporated
and Raymond James & Associates, Inc. are acting as
co-managers for the offering. The proposed offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The securities are being offered by Apellis pursuant to an
automatically effective shelf registration statement that was filed
with the Securities and Exchange Commission (“SEC”) on February 22,
2023.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to and describing the terms of the offering is
expected to be filed with the SEC and, if and when filed, copies of
the preliminary prospectus supplement relating to the offering may
be obtained for free by visiting the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus may also be obtained by contacting: J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717, by telephone at
866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, or by telephone at (866) 471-2526, or
by email at prospectus-ny@ny.email.gs.com; or Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
35th Floor, New York, New York 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com. The final
terms of the offering will be disclosed in a final prospectus
supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ApellisApellis Pharmaceuticals, Inc. is a
global biopharmaceutical company that combines courageous science
and compassion to develop life-changing therapies for some of the
most challenging diseases patients face. We ushered in the first
new class of complement medicine in 15 years and now have two
approved medicines targeting C3. These include the first and only
therapy for geographic atrophy, a leading cause of blindness around
the world. With nearly a dozen clinical and pre-clinical programs
underway, we believe we have only begun to unlock the potential of
targeting C3 across many serious diseases.
Forward-Looking StatementsStatements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements relating to the company’s anticipated public offering.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all and other factors discussed in the
“Risk Factors” section of the preliminary prospectus supplement to
be filed with the SEC, Apellis’ Annual Report on Form 10-K filed
with the SEC on February 21, 2023, and the risks described in other
filings that Apellis may make with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Apellis specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Media Contact:Lissa
Pavlukmedia@apellis.com617.977.6764
Investor Contact:Meredith
Kaya meredith.kaya@apellis.com617.599.8178
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024